SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Mometasone Ointment Formulation
Version
5.1

Revision Date:
09/30/2023

SDS Number:
1751223-00014

Date of last issue: 04/04/2023
Date of first issue: 06/14/2017

SECTION 1. IDENTIFICATION
Product name:

Mometasone Ointment Formulation

Manufacturer or supplier's details
Company name of supplier: Organon & Co.
Address: 30 Hudson Street, 33nd floor
Jersey City, New Jersey, U.S.A 07302
Telephone: 1-551-430-6000
Emergency telephone: 1-215-631-6999
E-mail address: EHSSTEWARD@organon.com
Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical
Restrictions on use: Not applicable
SECTION 2. HAZARDS IDENTIFICATIONGHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR
1910.1200)
Reproductive toxicity: Category 1B
GHS label elements
Hazard pictograms:

Signal Word:

DangerHazard Statements:

H360Df May damage the unborn child. Suspected of damaging
fertility.

Precautionary Statements:

Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been readand understood.
P280 Wear protective gloves, protective clothing, eye protection
and face protection.
Response:
P308 + P313 IF exposed or concerned: Get medical attention.
Storage:
P405 Store locked up.
Disposal:
P501 Dispose of contents and container to an approved waste
disposal plant.

1 / 21SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Mometasone Ointment Formulation
Version
5.1

Revision Date:
09/30/2023

SDS Number:
1751223-00014

Date of last issue: 04/04/2023
Date of first issue: 06/14/2017

Other hazards
None known.
SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substance / Mixture:

MixtureComponents
Chemical name
CAS-No.
Petrolatum
8009-03-8
2-Methyl-2,4-pentanediol
107-41-5
Propylene glycol monostearate
1323-39-3
Mometasone
83919-23-7
Actual concentration is withheld as a trade secretConcentration (% w/w)>= 70 - < 90>= 10 - < 20>= 1 - < 5>= 0.1 - < 1

SECTION 4. FIRST AID MEASURES
General advice:

In the case of accident or if you feel unwell, seek medical
advice immediately.
When symptoms persist or in all cases of doubt seek medical
advice.

If inhaled:

In case of skin contact:

In case of eye contact:

If swallowed:

Most important symptoms
and effects, both acute anddelayedProtection of first-aiders:

If inhaled, remove to fresh air.
Get medical attention.
In case of contact, immediately flush skin with soap and plentyof water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.
If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
May damage the unborn child. Suspected of damaging fertility.

Notes to physician::

First Aid responders should pay attention to self-protection,and use the recommended personal protective equipment
when the potential for exposure exists (see section 8).
Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES
Suitable extinguishing media:

Unsuitable extinguishingmedia
Specific hazards during firefighting::

Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical
None known.
Vapors may form explosive mixtures with air.
Exposure to combustion products may be a hazard to health.
2 / 21SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Mometasone Ointment Formulation
Version
5.1

Revision Date:
09/30/2023

SDS Number:
1751223-00014

Date of last issue: 04/04/2023
Date of first issue: 06/14/2017

Hazardous combustion products:

Carbon oxides

Specific extinguishing methods:

Special protective equipment
for fire-fighters:

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to doso.
Evacuate area.
In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protec- :tive equipment and emergency procedures

Use personal protective equipment.
Follow safe handling advice (see section 7) and personal
protective equipment recommendations (see section 8).

Environmental precautions:

Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages
cannot be contained.

Methods and materials forcontainment and cleaning up:

Sweep up or vacuum up spillage and collect in suitablecontainer for disposal.
Local or national regulations may apply to releases anddisposal of this material, as well as those materials and items
employed in the cleanup of releases. You will need todetermine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding
certain local or national requirements.

SECTION 7. HANDLING AND STORAGE
Technical measures:

Local/Total ventilation:

Advice on safe handling:

Conditions for safe storage:

See Engineering measures under EXPOSURE
CONTROLS/PERSONAL PROTECTION section.
If sufficient ventilation is unavailable, use with local exhaust
ventilation.
Do not get on skin or clothing.
Do not swallow.
Avoid contact with eyes.
Handle in accordance with good industrial hygiene and safety
practice, based on the results of the workplace exposure
assessment
Keep container tightly closed.
Take care to prevent spills, waste and minimize release to theenvironment.
Keep in properly labeled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.
3 / 21SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Mometasone Ointment Formulation
Version
5.1

Revision Date:
09/30/2023

SDS Number:
1751223-00014

Materials to avoid:

Date of last issue: 04/04/2023
Date of first issue: 06/14/2017

Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Ingredients with workplace control parameters
Components

CAS-No.

Petrolatum

8009-03-8

2-Methyl-2,4-pentanediol

107-41-5

Propylene glycol monostearate

1323-39-3

TWA (Inhalable particulate matter)
TWA (Respirable particulate matter)
83919-23-7
TWA
Further information: Skin
Wipe limit

Mometasone

Engineering measures

Value type
(Form ofexposure)
TWA (Inhalable particulate matter)
TWA (Mist)
TWA (Mist)
ST (Mist)
TWA (Vapor)
STEL (Vapor)
STEL (Inhalable fraction,
Aerosol only)C:

Control parameters / Permissible
concentration
5 mg/m³Basis

5 mg/m³
5 mg/m³
10 mg/m³
25 ppm50 ppmOSHA Z-1
NIOSH RELNIOSH REL
ACGIH
ACGIH

10 mg/m³

ACGIH

25 ppm
125 mg/m³
10 mg/m³

NIOSH REL

3 mg/m³

ACGIH

1 µg/m3 (OEB 4)Internal

10 µg/100 cm²Internal

ACGIH

ACGIH

Containment technologies suitable for controlling compounds
are required to control at source and to prevent migration of
the compound to uncontrolled areas (e.g., vacuum conveying
from a closed system, packout head with inflatable seal fromstationary container, ventilated enclosure, etc.).
All engineering controls should be implemented by facility
design and operated in accordance with GMP principles toprotect products, workers, and the environment.
Essentially no open handling permitted.
Use closed processing systems or containment technologies.

Personal protective equipment
Respiratory protection: General and local exhaust ventilation is recommended to
4 / 21SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Mometasone Ointment Formulation
Version
5.1

Revision Date:
09/30/2023

SDS Number:
1751223-00014

Date of last issue: 04/04/2023
Date of first issue: 06/14/2017

maintain vapor exposures below recommended limits. Where
concentrations are above recommended limits or are
unknown, appropriate respiratory protection should be worn.
Follow OSHA respirator regulations (29 CFR 1910.134) anduse NIOSH/MSHA approved respirators. Protection provided
by air purifying respirators against exposure to any
hazardous chemical is limited. Use a positive pressure air
supplied respirator if there is any potential for uncontrolled
release, exposure levels are unknown, or any othercircumstance where air purifying respirators may not provide
adequate protection.
Hand protection
Material:

Chemical-resistant gloves

Remarks
Eye protection::

Skin and body protection:

Hygiene measures:

Consider double gloving.
Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions,mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is apotential for direct contact to the face with dusts, mists, oraerosols.
Work uniform or laboratory coat.
Additional body garments should be used based upon thetask being performed (e.g., sleevelets, apron, gauntlets,
disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentiallycontaminated clothing.
If exposure to chemical is likely during typical use, provide
eye flushing systems and safety showers close to theworking place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review ofengineering controls, proper personal protective equipment,
appropriate degowning and decontamination procedures,industrial hygiene monitoring, medical surveillance and theuse of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES
Appearance:

ointment

Color:

white to off-white

Odor

:

No data available

Odor Threshold:

No data available

pH:

No data available

Melting point/freezing point:

No data available

Initial boiling point and boiling:

No data available
5 / 21SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Mometasone Ointment Formulation
Version
5.1

Revision Date:
09/30/2023

SDS Number:
1751223-00014

Date of last issue: 04/04/2023
Date of first issue: 06/14/2017

range
Flash point:> 199.9 °F / > 93.3 °C

Evaporation rate:

No data available

Flammability (solid, gas):

Not classified as a flammability hazard

Flammability (liquids):

Not applicable

Upper explosion limit / Upper
flammability limit:

No data available

Lower explosion limit / Lower
flammability limit:

No data available

Vapor pressure:

No data available

Relative vapor density:

No data available

Relative density:

No data available

Density:

No data available

Solubility(ies)
Water solubility:

No data available

Partition coefficient: noctanol/water
Autoignition temperature:

No data available:

No data available

Decomposition temperature:

No data available

Viscosity
Viscosity, kinematic:

No data available

Explosive properties:

Not explosive

Oxidizing properties:

The substance or mixture is not classified as oxidizing.

Molecular weight:

No data available

Particle size:

No data available

SECTION 10. STABILITY AND REACTIVITY
Reactivity
Chemical stability
Possibility of hazardous reactions:::

Not classified as a reactivity hazard.
Stable under normal conditions.
Vapors may form explosive mixture with air.
Can react with strong oxidizing agents.
6 / 21SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Mometasone Ointment Formulation
Version
5.1

Revision Date:
09/30/2023

SDS Number:
1751223-00014

Conditions to avoid
Incompatible materials
Hazardous decomposition
products:::

Date of last issue: 04/04/2023
Date of first issue: 06/14/2017

None known.
Oxidizing agents
No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION
Information on likely routes of exposure
Skin contact
Ingestion
Eye contact
Acute toxicity
Not classified based on available information.
Product:
Acute oral toxicity:

Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Petrolatum:
Acute oral toxicity:

LD50 (Rat): > 5,000 mg/kg
Method: OECD Test Guideline 401
Remarks: Based on data from similar materials

Acute dermal toxicity:

LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal
toxicity
Remarks: Based on data from similar materials

2-Methyl-2,4-pentanediol:
Acute oral toxicity:

LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 420

Acute dermal toxicity:

LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal
toxicity

Components:

Propylene glycol monostearate:
Acute oral toxicity: LD50 (Mouse): > 5,000 mg/kg
Mometasone:
Acute oral toxicity:

LD50 (Rat): > 2,000 mg/kg
LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity:

LC50 (Rat): > 3.3 mg/l
7 / 21SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Mometasone Ointment Formulation
Version
5.1

Revision Date:
09/30/2023

SDS Number:
1751223-00014

Date of last issue: 04/04/2023
Date of first issue: 06/14/2017

Exposure time: 4 h
Test atmosphere: dust/mist
Remarks: No mortality observed at this dose.
LC50 (Mouse): > 3.2 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Acute toxicity (other routes of :administration)

LD50 (Rat): 300 mg/kg
Application Route: Subcutaneous
Symptoms: Breathing difficulties

Skin corrosion/irritation
Not classified based on available information.
Components:
Petrolatum:Species
MethodResultRemarks::::

RabbitOECD Test Guideline 404
No skin irritation
Based on data from similar materials

2-Methyl-2,4-pentanediol:
Species
MethodResult:::RabbitOECD Test Guideline 404
No skin irritation

Propylene glycol monostearate:
Result: No skin irritation
Mometasone:
SpeciesResult::RabbitNo skin irritation

Serious eye damage/eye irritation
Not classified based on available information.
Components:
Petrolatum:SpeciesResult
MethodRemarks::::

RabbitNo eye irritation
OECD Test Guideline 405
Based on data from similar materials

2-Methyl-2,4-pentanediol:
SpeciesResult
Method:::RabbitNo eye irritation
OECD Test Guideline 405
8 / 21SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Mometasone Ointment Formulation
Version
5.1

Revision Date:
09/30/2023

Mometasone:
SpeciesResultSDS Number:
1751223-00014::

Date of last issue: 04/04/2023
Date of first issue: 06/14/2017

RabbitNo eye irritation

Respiratory or skin sensitization
Skin sensitization
Not classified based on available information.
Respiratory sensitization
Not classified based on available information.
Components:
Petrolatum:
Test Type
Routes of exposure
SpeciesResultRemarks:::::

Buehler Test
Skin contact
Guinea pig
negative
Based on data from similar materials

2-Methyl-2,4-pentanediol:
Test Type
Routes of exposure
Species
MethodResult:::::Maximization Test
Skin contact
Guinea pig
OECD Test Guideline 406
negative

Mometasone:
Test Type
Routes of exposure
Species
Assessment
ResultRemarks

:
:
:
:
:
:

Maximization Test
DermalGuinea pig
Does not cause skin sensitization.
negative
The results of a test on guinea pigs showed this substance tobe a weak skin sensitizer.

Germ cell mutagenicity
Not classified based on available information.
Components:
Petrolatum:
Genotoxicity in vitro:

Test Type: Chromosome aberration test in vitro
Result: negative
Remarks: Based on data from similar materials

Genotoxicity in vivo:

Test Type: Mammalian erythrocyte micronucleus test (in vivo
cytogenetic assay)
Species: Mouse
9 / 21SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Mometasone Ointment Formulation
Version
5.1

Revision Date:
09/30/2023

SDS Number:
1751223-00014

Date of last issue: 04/04/2023
Date of first issue: 06/14/2017

Application Route: Intraperitoneal injection
Method: OECD Test Guideline 474
Result: negative
Remarks: Based on data from similar materials
2-Methyl-2,4-pentanediol:
Genotoxicity in vitro:

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 476
Result: negative
Test Type: Chromosome aberration test in vitro
Result: negative

Mometasone:
Genotoxicity in vitro:

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: Chromosomal aberration
Test system: Chinese hamster lung cells
Result: negative
Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: positive
Test Type: Mouse Lymphoma
Result: negative

Genotoxicity in vivo:

Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative
Test Type: Chromosomal aberration
Species: Rat
Cell type: Bone marrow
Result: negative
Test Type: unscheduled DNA synthesis assay
Species: Rat
Cell type: Liver cells
Result: negative

Germ cell mutagenicity Assessment:

Weight of evidence does not support classification as a germ
cell mutagen.

Carcinogenicity
Not classified based on available information.

10 / 21

SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Mometasone Ointment Formulation
Version
5.1

Revision Date:
09/30/2023

SDS Number:
1751223-00014

Date of last issue: 04/04/2023
Date of first issue: 06/14/2017

Components:
Petrolatum:Species
Application RouteExposure time
Result

:
:
:
:

Rat
Ingestion
2 Years
negative

Mometasone:
Species
Application RouteExposure time
Dose
Result

:
:
:
:
:

Rat
Inhalation
2 Years
0.067 mg/kg body weight
negative

Species
Application RouteExposure time
Dose
Result

:
:
:
:
:

Mouse
Inhalation
19 Months
0.160 mg/kg body weight
negative

IARC

No ingredient of this product present at levels greater than or equal to 0.1% isidentified as probable, possible or confirmed human carcinogen by IARC.

OSHA

No component of this product present at levels greater than or equal to 0.1% is
on OSHA’s list of regulated carcinogens.

NTP

No ingredient of this product present at levels greater than or equal to 0.1% isidentified as a known or anticipated carcinogen by NTP.

Reproductive toxicity
May damage the unborn child. Suspected of damaging fertility.
Components:
Petrolatum:
Effects on fertility:

Test Type: Reproduction/Developmental toxicity screening
test
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

Effects on fetal development:

Test Type: Embryo-fetal development
Species: Rat
Application Route: Skin contact
Result: negative
Remarks: Based on data from similar materials

2-Methyl-2,4-pentanediol:
Effects on fertility:

Test Type: One-generation reproduction toxicity study
Species: Rat
11 / 21

SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Mometasone Ointment Formulation
Version
5.1

Revision Date:
09/30/2023

SDS Number:
1751223-00014

Date of last issue: 04/04/2023
Date of first issue: 06/14/2017

Application Route: Ingestion
Method: OECD Test Guideline 443
Result: negative
Effects on fetal development:

Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 443
Result: positive

Reproductive toxicity - Assessment:

Some evidence of adverse effects on development, based onanimal experiments.

Mometasone:
Effects on fertility:

Test Type: Fertility
Species: Rat
Application Route: Subcutaneous
Fertility: NOAEL: 0.015 mg/kg body weight
Symptoms: Reduced embryonic survival, Reduced fetal
weight.
Result: No effects on fertility., Effect on reproduction capacity.

Effects on fetal development:

Test Type: Embryo-fetal development
Species: Mouse
Application Route: Subcutaneous
Embryo-fetal toxicity.: LOAEL: 0.06 mg/kg body weight
Result: Embryotoxic effects., Teratogenicity anddevelopmental toxicity
Test Type: Embryo-fetal development
Species: Rat
Application Route: Dermal
Embryo-fetal toxicity.: LOAEL: 0.3 mg/kg body weight
Result: Embryo-fetal toxicity.
Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Dermal
Embryo-fetal toxicity.: LOAEL: 0.15 mg/kg body weight
Result: Embryo-fetal toxicity., Malformations were observed.
Test Type: Embryo-fetal development
Species: Rat
Application Route: Subcutaneous
Embryo-fetal toxicity.: LOAEL: 0.15 mg/kg body weight
Result: Effects on newborn.
Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Embryo-fetal toxicity.: LOAEL: 0.7 mg/kg body weight
Result: Embryo-fetal toxicity., Malformations were observed.

12 / 21

SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Mometasone Ointment Formulation
Version
5.1

Revision Date:
09/30/2023

Reproductive toxicity - Assessment

SDS Number:
1751223-00014:

Date of last issue: 04/04/2023
Date of first issue: 06/14/2017

Clear evidence of adverse effects on development, based onanimal experiments., Some evidence of adverse effects on
sexual function and fertility, based on animal experiments.

STOT-single exposure
Not classified based on available information.
Components:
Mometasone:
Remarks:

Based on available data, the classification criteria are not met.

STOT-repeated exposure
Not classified based on available information.
Components:
Mometasone:
Routes of exposure
Target Organs
Assessment:::

inhalation (dust/mist/fume)
Immune system, Liver, Kidney, Skin
May cause damage to organs through prolonged or repeatedexposure.

Petrolatum:Species
NOAEL
Application RouteExposure time

:
:
:
:

Rat
5,000 mg/kg
Ingestion
2y2-Methyl-2,4-pentanediol:
Species
NOAEL
Application RouteExposure time
Method

:
:
:
:
:

Rat
>= 450 mg/kg
Ingestion
13 Weeks
OECD Test Guideline 408

Mometasone:
Species
NOAEL
LOAEL
Application RouteExposure timeTarget Organs

:
:
:
:
:
:

Rat
0.005 mg/kg
0.3 mg/kg
Oral
30 d
Lymph nodes, Liver, Adrenal gland, Skin, thymus glandSpecies
LOAEL
Application Route

:
:
:

Dog
0.5 mg/kg
Oral

Repeated dose toxicity
Components:

13 / 21

SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Mometasone Ointment Formulation
Version
5.1

Revision Date:
09/30/2023

SDS Number:
1751223-00014

Date of last issue: 04/04/2023
Date of first issue: 06/14/2017

Exposure timeTarget Organs

:
:

30 d
Lymph nodes, Liver, Adrenal gland, Skin, thymus glandSpecies
NOAEL
Application RouteExposure timeTarget Organs

:
:
:
:
:

Rat
0.00013 mg/l
inhalation (dust/mist/fume)
90 dAdrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,
Kidney, Liver, thymus glandSpecies
NOAEL
Application RouteExposure timeTarget Organs

:
:
:
:
:

Dog
0.0005 mg/l
inhalation (dust/mist/fume)
90 dAdrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,
Kidney, thymus gland, Liver

Aspiration toxicity
Not classified based on available information.
Components:
Mometasone:
Not applicable
Experience with human exposure
Components:
2-Methyl-2,4-pentanediol:
Eye contact:

Target Organs: Eyes
Symptoms: Irritation

Mometasone:
Inhalation:

Skin contact:

Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain,
musculoskeletal pain, immune system effects, indigestion
Symptoms: Dermatitis, Itching:

Dermal absorption possible

Further information
Components:
Mometasone:
Remarks

SECTION 12. ECOLOGICAL INFORMATION
Ecotoxicity
Components:
Petrolatum:
14 / 21

SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Mometasone Ointment Formulation
Version
5.1

Revision Date:
09/30/2023

SDS Number:
1751223-00014

Date of last issue: 04/04/2023
Date of first issue: 06/14/2017

Toxicity to fish:

LL50 (Pimephales promelas (fathead minnow)): > 100 mg/l
Exposure time: 96 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 203
Remarks: Based on data from similar materials

Toxicity to daphnia and otheraquatic invertebrates:

EC50 (Daphnia magna (Water flea)): > 10,000 mg/l
Exposure time: 48 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Toxicity to algae/aquaticplants:NOEL (Pseudokirchneriella subcapitata (green algae)): >=100 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to daphnia and other :aquatic invertebrates (Chronic toxicity)

2-Methyl-2,4-pentanediol:
Toxicity to fish

NOEC (Daphnia magna (Water flea)): 10 mg/l
Exposure time: 21 d
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials:

LC50 (Gambusia affinis (Mosquito fish)): 8,510 mg/l
Exposure time: 96 h

Toxicity to daphnia and otheraquatic invertebrates:

EC50 (Ceriodaphnia dubia (water flea)): 2,800 mg/l
Exposure time: 48 h

Toxicity to algae/aquaticplants:

ErC50 (Raphidocelis subcapitata (freshwater green alga)): >429 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
EC10 (Raphidocelis subcapitata (freshwater green alga)): >429 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to daphnia and other :aquatic invertebrates (Chronic toxicity)

NOEC (Daphnia magna (Water flea)): 25 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms:

NOEC (Bacteria): 200 mg/l
Exposure time: 10 d

Mometasone:
Toxicity to fish:

LC50 (Menidia beryllina (Silverside)): 0.11 mg/l
Exposure time: 96 h
Remarks: No toxicity at the limit of solubility.

15 / 21

SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Mometasone Ointment Formulation
Version
5.1

Revision Date:
09/30/2023

SDS Number:
1751223-00014

Date of last issue: 04/04/2023
Date of first issue: 06/14/2017

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l
Exposure time: 7 dRemarks: No toxicity at the limit of solubility.
Toxicity to daphnia and otheraquatic invertebrates:

EC50 (Daphnia magna (Water flea)): > 5 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility.
EC50 (Americamysis): > 5 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035
Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquaticplants:

EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2
mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity):

NOEC (Pimephales promelas (fathead minnow)): 0.00014
mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other :aquatic invertebrates (Chronic toxicity)

NOEC (Daphnia magna (Water flea)): 0.34 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms

EC50: > 1,000 mg/l
Exposure time: 3 hTest Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility.

:

NOEC: 1,000 mg/l
Exposure time: 3 hTest Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility.
Persistence and degradability
Components:
Petrolatum:
Biodegradability:

Result: Not readily biodegradable.
Biodegradation: 31 %Exposure time: 28 d
Method: OECD Test Guideline 301F
Remarks: Based on data from similar materials

16 / 21

SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Mometasone Ointment Formulation
Version
5.1

Revision Date:
09/30/2023

SDS Number:
1751223-00014

Date of last issue: 04/04/2023
Date of first issue: 06/14/2017

2-Methyl-2,4-pentanediol:
Biodegradability:

Result: Readily biodegradable.
Biodegradation: 81 %Exposure time: 28 d
Method: OECD Test Guideline 301F

Mometasone:
Biodegradability:

Result: Not readily biodegradable.
Biodegradation: 50 %Exposure time: 28 d
Method: OECD Test Guideline 314

Stability in water:

Hydrolysis: 50 %(12 d)
Method: OECD Test Guideline 111:

log Pow: < 4
Remarks: Calculation:

Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 107.1
Method: OECD Test Guideline 305:

log Pow: 4.68:

log Koc: 4.02

Bioaccumulative potential
Components:
2-Methyl-2,4-pentanediol:
Partition coefficient: noctanol/water
Mometasone:
Bioaccumulation

Partition coefficient: noctanol/water
Mobility in soil
Components:
Mometasone:
Distribution among environmental compartments
Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS
Disposal methods
Waste from residues:

Contaminated packaging:

Dispose of in accordance with local regulations.
Do not dispose of waste into sewer.
Empty containers should be taken to an approved waste
handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

17 / 21

SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Mometasone Ointment Formulation
Version
5.1

Revision Date:
09/30/2023

SDS Number:
1751223-00014

Date of last issue: 04/04/2023
Date of first issue: 06/14/2017

SECTION 14. TRANSPORT INFORMATIONInternational Regulations
UNRTDGUN number
Proper shipping name

:
:

Class
Packing group
LabelsEnvironmentally hazardous

:
:
:
:

IATA-DGR
UN/ID No.
Proper shipping name::UN 3077
ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,
N.O.S.
(Mometasone)
9
III
9
yes

:
:
:
:

UN 3077
Environmentally hazardous substance, solid, n.o.s.
(Mometasone)
9
III
Miscellaneous
956

:

956

:

yes

IMDG-CodeUN number
Proper shipping name

:
:

Class
Packing group
LabelsEmS Code
Marine pollutant

:
:
:
:
:

UN 3077
ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,
N.O.S.
(Mometasone)
9III
9
F-A, S-F
yes

Class
Packing group
LabelsPacking instruction (cargo
aircraft)Packing instruction (passenger aircraft)
Environmentally hazardous

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC CodeNot applicable for product as supplied.
Domestic regulation
49 CFR
UN/ID/NA number
Proper shipping name

:
:

Class
Packing group
LabelsERG Code
Marine pollutant
Remarks

:
:
:
:
:
:

UN 3077
Environmentally hazardous substance, solid, n.o.s.
(Mometasone)
9
III
CLASS 9171
yes(Mometasone)
Above applies only to containers over 119 gallons or 450
liters.
Shipment by ground under DOT is non-regulated; however it
18 / 21

SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Mometasone Ointment Formulation
Version
5.1

Revision Date:
09/30/2023

SDS Number:
1751223-00014

Date of last issue: 04/04/2023
Date of first issue: 06/14/2017

may be shipped per the applicable hazard classification tofacilitate multi-modal transport involving ICAO (IATA) or IMO.
Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely
based upon the properties of the unpackaged material as it is described within this Safety Data
Sheet. Transportation classifications may vary by mode of transportation, package sizes, andvariations in regional or country regulations.
SECTION 15. REGULATORY INFORMATIONCERCLA Reportable Quantity
Listed substances in the product are at low enough levels to not be expected to exceed the RQ
SARA 304 Extremely Hazardous Substances Reportable Quantity
This material does not contain any components with a section 304 EHS RQ.
SARA 302 Extremely Hazardous Substances Threshold Planning Quantity
This material does not contain any components with a section 302 EHS TPQ.
SARA 311/312 Hazards:

Reproductive toxicity

SARA 313:

This material does not contain any chemical components withknown CAS numbers that exceed the threshold (De Minimis)
reporting levels established by SARA Title III, Section 313.

US State Regulations
Pennsylvania Right To Know
Petrolatum
2-Methyl-2,4-pentanediol
Beeswax
Water

8009-03-8
107-41-5
8006-40-4
7732-18-5

California List of Hazardous Substances
Petrolatum
2-Methyl-2,4-pentanediol

8009-03-8
107-41-5

California Permissible Exposure Limits for Chemical Contaminants
Petrolatum
2-Methyl-2,4-pentanediol

8009-03-8
107-41-5

The ingredients of this product are reported in the following inventories:
AICS: not determinedDSL:

not determined

IECSC

:

not determined

SECTION 16. OTHER INFORMATION
Further information
19 / 21

SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Mometasone Ointment Formulation
Version
5.1

Revision Date:
09/30/2023

SDS Number:
1751223-00014

NFPA 704:

Date of last issue: 04/04/2023
Date of first issue: 06/14/2017
HMIS® IV:

Flammability

HEALTH1
Health00Special hazard*

0

FLAMMABILITY

1

PHYSICAL HAZARD

0

Instability

HMIS® ratings are based on a 0-4 rating
scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents
a chronic hazard, while the "/" represents
the absence of a chronic hazard.

Full text of other abbreviations
ACGIH: USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL
: USA. NIOSH Recommended Exposure Limits
OSHA Z-1: USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA: 8-hour, time-weighted average
ACGIH / STEL
: Short-term exposure limit
NIOSH REL / TWA: Time-weighted average concentration for up to a 10-hour
workday during a 40-hour workweek
NIOSH REL / ST
: STEL - 15-minute TWA exposure that should not be exceededat any time during a workday
NIOSH REL / C: Ceiling value not be exceeded at any time.
OSHA Z-1 / TWA: 8-hour time weighted average
AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing ofMaterials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation,and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of theGerman Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule;
ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with
x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC International Agency for Research on Cancer; IATA - International Air Transport Association; IBC- International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals
in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime
Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health
Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to
50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse)
20 / 21

SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Mometasone Ointment Formulation
Version
5.1

Revision Date:
09/30/2023

SDS Number:
1751223-00014

Date of last issue: 04/04/2023
Date of first issue: 06/14/2017

Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable
Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory ofChemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Officeof Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act;REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable
Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical SubstanceInventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act(United States); UN - United Nations; UNRTDG - United Nations Recommendations on theTransport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used tocompile the Material Safety
Data Sheet:Internal technical data, data from raw material SDSs, OECD
eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

Revision Date:

09/30/2023

The information provided in this Safety Data Sheet is correct to the best of our knowledge,
information and belief at the date of its publication. The information is designed only as a
guidance for safe handling, use, processing, storage, transportation, disposal and release andshall not be considered a warranty or quality specification of any type. The information provided
relates only to the specific material identified at the top of this SDS and may not be valid when the
SDS material is used in combination with any other materials or in any process, unless specified
in the text. Material users should review the information and recommendations in the specificcontext of their intended manner of handling, use, processing and storage, including anassessment of the appropriateness of the SDS material in the user’s end product, if applicable.
US / Z8

21 / 21